09/780,575

```
FILE 'CAPLUS' ENTERED AT 13:30:17 ON 27 JUL 2004
           2850 S ICS
L1
              0 S L1 AND GAL180
L2
              0 S L1 AND NTA
L3
              5 S L1 AND REPRESSOR?
             31 S LEPB
L5
              1 S L1 AND L5
L6
     FILE 'REGISTRY' ENTERED AT 13:40:00 ON 27 JUL 2004
              1 S NEAYVHDGPVRSLN/SQSP
L7
     FILE 'CAPLUS, TOXCENTER, USPATFULL' ENTERED AT 13:40:45 ON 27 JUL 2004
              3 S L7
rs
              1 DUP REM L8 (2 DUPLICATES REMOVED)
L9
            112 S (INTERLEUKIN) (3A) (CONVERTASE?)
L10
             14 S L10 AND REPRESSOR?
L11
             14 DUP REM L11 (0 DUPLICATES REMOVED)
T<sub>1</sub>12
     FILE 'REGISTRY' ENTERED AT 13:44:55 ON 27 JUL 2004
L13
             38 S KARKEAELAAATAEQ/SQSP
     FILE 'CAPLUS' ENTERED AT 13:45:17 ON 27 JUL 2004
L14
             26 DUP REM L14 (0 DUPLICATES REMOVED)
L15
           1147 S (LAMBDA) (3A) (REPRESSOR?)
L16
             49 S L16 AND (ANTIGEN? OR EPITOPE?)
L17
L18
              1 S L17 AND LIBRAR?
L19
            107 S L16 AND PEPTIDE?
              5 S L19 AND LIBRAR?
L20
L21
              5 DUP REM L20 (0 DUPLICATES REMOVED)
     FILE 'CAPLUS, EMBASE, BIOSIS, MEDLINE, WPIDS' ENTERED AT 13:52:51 ON 27
     JUL 2004
            355 S (KODADEK, T? OR KODADEK T?)/AU, IN
L22
L23
             24 S L22 AND REPRESSOR?
L24
             16 DUP REM L23 (8 DUPLICATES REMOVED)
L25
          44384 S LACZ
L26
           2676 S L25 AND REPRESSOR?
L27
            343 S L26 AND LAMBDA
             21 S L27 AND (PEPTID? OR PEPTOID? OR EPITOPE?)
L28
             12 DUP REM L28 (9 DUPLICATES REMOVED)
L29
         258773 S (DNA OR CIS) (3A) (BINDING)
L30
L31
           3989 S L30 AND OPERATOR?
L32
            511 S L31 AND FUSION?
            392 S L32 AND (PEPTIDE? OR PROTEIN?) (3A) (INTERACT? OR BIND?)
L33
              0 S L33 AND (B-GAL?)
L34
L35
             84 S L33 AND (LAC?) (3A) (OPERON? OR OPERATOR?)
             64 S L35 AND REPRESSOR?
L36
L37
             39 DUP REM L36 (25 DUPLICATES REMOVED)
L38
             18 S (REPRESSOR?) (3A) (RECONSTIT?)
L39
             9 DUP REM L38 (9 DUPLICATES REMOVED)
```

=>

(FILE 'HOME' ENTERED AT 13:28:19 ON 27 JUL 2004)

```
ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
L18
     1993:464906 CAPLUS
AN
DN
     119:64906
     Generation and selection of novel DNA-binding proteins
TI
     Ladner, Robert C.; Guterman, Sonia K.; Kent, Rachel B.; Ley, Arthur C.
IN
     Protein Engineering Corp., USA
PA.
     U.S., 145 pp. Cont.-in-part of U.S. 5,096,815.
SO
     CODEN: USXXAM
DT
     Patent
LA
     English
FAN.CNT 2
                                           APPLICATION NO. DATE
                      KIND DATE
     PATENT NO.
                     _ - - -
                           _____
                            19930330
                                           US 1990-558011
                                                            19900726
                      Α
PI
     US 5198346
                                           US 1989-293980
                                                            19890106
     US 5096815
                      Α
                            19920317
                                           AU 1990-49588
                                                            19900105
                            19900813
     AU 9049588
                      A1
                                           EP 1990-902453
                                                            19900105
                            19911023
     EP 452413
                      A1
                            20000412
                      B1
     EP 452413
         R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE
                                                            19900105
                                           JP 1990-502436
```

=> d ab

JP 04504052

WO 1990-US24

AT 191746

PRAI US 1989-293980

ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN L18

T2 19920723

20000415 19890106

19900105

E

A2

Α

A method for selecting a pair of genes encoding proteins that bind to AB homooligomeric DNA (DBPs) and that associate to form a hybrid hetero-oligomeric protein that binds to a predetd. nonpalindromic, double-stranded DNA target sequence is described. The genes are selected in cells that have first been transformed with a selection vector containing 2 operons, each operon containing a promoter, a target sequence, and a selectable or screenable gene. These cells are also transformed with a 2nd vector containing a DBP gene that has been mutagenized by a non-specific process. Binding of a DBP analog produced by the mutant gene to the target sequence gives the cell a selective advantage; alternatively, the expression of the screenable gene is blocked. The method was used to modify the phage .lambda. Cro repressor to enable it to bind to an HIV-1 sequence. The selection system comprised a selectable gene, aadA (which confers spectinomycin resistance), and a screenable gene, tet. The operon containing the selectable gene consisted of the aadA gene with its natural promoter and occluding promoter Pcon followed by the target sequence. Upon binding of a DBP to the target sequence, expression from Pcon is inhibited and aadA is expressed. Tet gene expression was driven by Pneo.

19900105

AT 1990-902453

=>

```
ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
     2002:933401 CAPLUS
AN
     138:249140
DN
     Screening peptide/protein libraries fused to the .
TI
     lambda. repressor DNA-binding domain in E. coli cells
     Marino-Ramirez, Leonardo; Campbell, Lisa; Hu, James C.
ΑU
     Center for Macromolecular Design, Department of Biochemistry and
CS
     Biophysics, Texas A&M University, College Station, TX, USA
     Methods in Molecular Biology (Totowa, NJ, United States) (2003), 205(E.
SO
     coli Gene Expression Protocols), 235-250
     CODEN: MMBIED; ISSN: 1064-3745
     Humana Press Inc.
PB
DT
     Journal
     English
LA
              THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 26
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
L21 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
     1999:450862 CAPLUS
AN
DN
     131:83957
     Interaction trap assay and its reagents
TТ
     Dove, Simon; Joung, J. Keith; Hochschild, Ann
IN
     President & Fellows of Harvard College, USA
PA
     U.S., 28 pp.
SO
     CODEN: USXXAM
DT
     Patent
     English
LA
FAN.CNT 2
                                           APPLICATION NO. DATE
     PATENT NO.
                      KIND DATE
                                           _____
                      _____
                                           US 1997-920015
                                                            19970826
                            19990720
PΤ
     US 5925523
                      Α
                                           US 1999-296204
                                                            19990421
                      B1
                            20010313
     US 6200759
                      P
                            19960823
PRAI US 1996-24484P
     US 1997-918612
                      В2
                            19970822
     US 1997-920015
                      A1
                            19970826
              THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 32
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
    ANSWER 3 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
L21
AN
     1999:274931 CAPLUS
     131:111988
DN
     Genetic selection of short peptides that support protein
TT
     oligomerization in vivo
     Zhang, Zhiwen; Murphy, Anne; Hu, James C.; Kodadek, Thomas
AU
     Department of Chemistry and Biochemistry, University of Texas at Austin,
CS
     Austin, TX, 78712, USA
     Current Biology (1999), 9(8), 417-420
SO
     CODEN: CUBLE2; ISSN: 0960-9822
     Current Biology Publications
PB '
DΤ
     Journal
LA
     English
              THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 24
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
L21 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
     1999:760778 CAPLUS
AN
     132:147291
DN
     A genetic screen to identify sequences that mediate protein
TI
     oligomerization in Escherichia coli
     Jappelli, Roberto; Brenner, Sydney
AU
     Molecular Sciences Institute, Berkeley, CA, 94704, USA
CS
     Biochemical and Biophysical Research Communications (1999), 266(1),
SO
     243-247
```

```
DT
    Journal
LA
    English
RE.CNT 21
             THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
             ALL CITATIONS AVAILABLE IN THE RE FORMAT
    ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
T<sub>2</sub>1
     1998:151232 CAPLUS
AN
DN
     128:201791
    An interaction trap assay system using the .lambda.
ΤI
    repressor for use in a bacterial host
IN
    Dove, Simon; Joung, J. Keith; Hochschild, Ann
    President and Fellows of Harvard College, USA
PΑ
    PCT Int. Appl., 63 pp.
SO
    CODEN: PIXXD2
DT
    Patent
    English
LA
FAN.CNT 2
    PATENT NO.
                     KIND DATE
                                         APPLICATION NO. DATE
                    ____
                                          -----
    WO 9807845
                     A1
                         19980226
                                          WO 1997-US14860 19970822
PΙ
        W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
            DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
            RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN,
            AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
            GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
            GN, ML, MR, NE, SN, TD, TG
    AU 9741596
                     A1
                          19980306
                                          AU 1997-41596
                                                           19970822
PRAI US 1996-24484P
                      Þ
                           19960823
    WO 1997-US14860
                      W
                           19970822
             THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 6
             ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

=> d 5 ab

PB

L21 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN

CODEN: BBRCA9; ISSN: 0006-291X

Academic Press

AB An interaction trap or two-hybrid system designed for use in a prokaryotic, i.e. bacterial, host is described. The system is generally similar to those designed for use with yeast but using components derived solely from prokaryotes. In particular a system using fusion proteins of the .lambda. cI repressor that bind an OR2 operator in a modified lacP/O promoter-operator region is described. The second component of the binding assay may be a fusion protein of the α or α subunits of the bacterial RNA polymerase. Alternatively, the LexA repressor may be used in combination with the SOS box.

```
ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 5
L24
     1998:435315 CAPLUS
ΑN
DN
     129:157351
ED
     Entered STN: 15 Jul 1998
ΤI
     Small-molecule-based strategies for controlling gene expression
AIJ
     Denison, Carilee; Kodadek, Thomas
CS
     Center for Biomedical Inventions, Departments of Internal Medicine and
     Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX,
     75235-8573, USA
SO
     Chemistry & Biology (1998), 5(6), R129-R145
     CODEN: CBOLE2; ISSN: 1074-5521
PB
     Current Biology Ltd.
DT
     Journal; General Review
LA
     English
     3-0 (Biochemical Genetics)
CC
     Section cross-reference(s): 1, 6
AB
     A review with 110 refs. A central goal in chemical biol. is to gain control
     over biol. pathways using small mols., and the mRNA-synthesizing machinery
     is a particularly important target. New advances in our understanding of
     transcriptional regulation suggests strategies to manipulate these
     pathways using small mols.
     gene expression regulation small mol review; transcription factor signal
ST
     transduction regulation review
IT
     Proteins, specific or class
     RL: BAC (Biological activity or effector, except adverse); BPR (Biological
     process); BSU (Biological study, unclassified); BIOL (Biological study);
        (DNA-binding, small-mol.-based strategies for controlling gene
        expression)
IT
     Immunosuppressants
        (effect on gene expression; small-mol.-based strategies for controlling
        gene expression)
ΙT
        (expression; small-mol.-based strategies for controlling gene
        expression)
IT
     DNA
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (interaction with proteins; small-mol.-based strategies for controlling
        gene expression)
IT
     Transcription factors
     RL: BAC (Biological activity or effector, except adverse); BPR (Biological
     process); BSU (Biological study, unclassified); BIOL (Biological study);
```

(repressors; small-mol.-based strategies for controlling gene

PROC (Process)

IT

expression)

Proteins, specific or class

- L29 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN
- AN 1999:385780 CAPLUS
- DN 131:165864
- TI A two-hybrid dual bait system to discriminate specificity of protein interactions
- AU Serebriiskii, Ilya; Khazak, Vladimir; Golemis, Erica A.
- CS Division of Basic Science, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA
- SO Journal of Biological Chemistry (1999), 274(24), 17080-17087 CODEN: JBCHA3; ISSN: 0021-9258
- PB American Society for Biochemistry and Molecular Biology
- DT Journal
- LA English
- Biol. regulatory systems require the specific organization of proteins AΒ into multicomponent complexes. Two hybrid systems have been used to identify novel components of signaling networks based on interactions with defined partner proteins. An important issue in the use of two-hybrid systems has been the degree to which interacting proteins distinguish their biol. partner from evolutionarily conserved related proteins and the degree to which observed interactions are specific. We adapted the basic two-hybrid strategy to create a novel dual bait system designed to allow single-step screening of libraries for proteins that interact with protein 1 of interest, fused to DNA binding domain A (LexA), but do not interact with protein 2, fused to DNA binding domain B (.lambda. cI). Using the selective interactions of Ras and Krev-1(RaplA) with Raf, RalGDS, and Krit1 as a model, we systematically compared LexA- and cI-fused baits and reporters. The LexA and cI bait reporter systems are well matched for level of bait expression and sensitivity range for interaction detection and allow effective isolation of specifically interacting protein pairs against a nonspecific background. These reagents should prove useful to refine the selectivity of library screens, to reduce the isolation of false positives in such screens, and to perform directed analyses of sequence elements governing the interaction of a single protein with multiple partners.
- RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 39 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 12 L37

AN1985:574943 CAPLUS

103:174943 DN

Novel method for identifying sequence-specific DNA-TТ binding proteins

Levens, David; Howley, Peter M. ΑU

Lab. Pathol., Natl. Cancer Inst., Bethesda, MD, 20205, USA

Molecular and Cellular Biology (1985), 5(9), 2307-15 SO CODEN: MCEBD4; ISSN: 0270-7306

 \mathtt{DT} Journal

CS

LA

English A general method was developed for the enrichment and identification of AΒ sequence-specific DNA binding proteins. A well-characterized protein-DNA interaction is used to isolate from crude cellular exts. or fractions thereof proteins which bind to specific DNA sequences; the method is based solely on this binding property of the proteins. The DNA sequence of interest, cloned adjacent to the lac operator DNA segment is incubated with a lac repressor -β-galactosidase fusion protein which retains full operator and inducer binding properties. The DNA fragment bound to the lac repressor-β-galactosidase fusion protein is precipitated by the addition of affinity-purified anti- β galactosidase immobilized on beads. This forms an affinity matrix for any proteins which might interact specifically with the DNA sequence cloned adjacent to the lac operator. When incubated with cellular exts. in the presence of excess competitor DNA, any protein(s) which specifically binds to the cloned DNA sequence of interest can be cleanly precipitated. When isopropyl- β -Dthiogalactopyranoside is added, the lac repressor releases the bound DNA, and thus the protein-DNA complex consisting of the specific restriction fragment and any specific binding protein (s) is released, permitting the identification of the protein by standard biochem. techniques. The utility of this method is demonstrated with the lambda repressor, another well-characterized DNAbinding protein, as a model. In addition, with crude prepns. of the yeast mitochondrial RNA polymerase, a 70,000-mol.-weight peptide was identified which binds specifically to the promoter region of the yeast mitochondrial 14S rRNA gene.

```
ANSWER 16 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN
L37
     1998:388645 CAPLUS
AN
     129:51713
DN
    Ligand detection system and its use in identifying ligands specifically
TΤ
    binding to protein domains
     Li, Min; Stricker, Nicole L.; Bredt, David S.; Christopherson, Karen S.
TN
     Johns Hopkins University, USA; Li, Min; Stricker, Nicole L.; Bredt, David
PA
     S.; Christopherson, Karen S.
SO
     PCT Int. Appl., 94 pp.
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
                                          APPLICATION NO. DATE
                     KIND DATE
     PATENT NO.
                           -----
                     ----
     ______
                                          WO 1997-US21861 19971126
                           19980604
PΙ
     WO 9823781
                      A1
        W: AU, CA, US
        RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
                           19980622
                                          AU 1998-74109
                                                            19971126
                     A1
     AU 9874109
PRAI US 1996-31793P
                      P
                            19961126
                           19970415
     US 1997-43560P
                      Р
                      W
                           19971126
     WO 1997-US21861
     The present invention relates to novel ligand detection systems and
AB
     methods of using the systems to identify ligands capable of specifically
     binding orphan protein domains. The invention also
     relates to peptide ligands capable of specifically binding an orphan
     domain of interest such as the PDZ domain of neuronal nitric oxide
     synthase (nNOS). Further provided are methods of detecting the peptide
     ligands and those orphan protein domains capable of specifically
     binding the peptide ligands. The present invention is
     useful for a variety of applications including detecting peptide ligands
     with therapeutic capacity to treat human diseases. To determine optimal
     peptide binding ligands for the nNOS PDZ domain, a
     fusion protein library was constructed that contained 15
     randomized residues at the C-terminus. In this library, a degenerate
     oligonucleotide encoding the random peptides was fused to the end of the
     Escherichia coli lac repressor. Following expression, the lac
     repressor protein binds to the lac
     operator sequence on the same plasmid linking each randomized
     15-mer peptide to the plasmid encoding that peptide. This linkage allowed
     repeated rounds of selection for specific peptide ligands in the
     population by affinity purification of peptide-repressor-plasmid
     complexes. Binding affinity was 8-100 nM for 95 out of 150 clones
     specifically interacting with nNOS-PDZ but not with control. Plasmids
     from these nNOS-specific clones were sequenced and the deduced peptide
     amino acid sequences were aligned via their C-termini. The optimal
     sequence is D-X-V-COOH. A search was made of the D-X-V pattern at the
```

There were 484 matches in the database.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

C-terminus of protein sequences in a non-redundant protein database.

```
ANSWER 13 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN
L37
     1999:359663 CAPLUS
AN
DN
     131:1457
     Methods for production of recombinant lac repressor proteins
TΙ
     with altered ligand responsivity
     Matthews, Kathleen S.; Swint-Kruse, Liskin
IN
     William Marsh Rice University, USA
PA
     PCT Int. Appl., 29 pp.
SO
     CODEN: PIXXD2
DT
     Patent
LΑ
     English
FAN.CNT 2
                                           APPLICATION NO. DATE
     PATENT NO.
                      KIND DATE
                      _ _ _ _
                            19990603
                                           WO 1998-US24949 19981120
PΙ
     WO 9927108
                       A1
         W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,
             KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
             NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
             UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                            19990615
                                           AU 1999-14673
                                                             19981120
     AU 9914673
                       A1
                                           US 2002-197053
                                                             20020717
     US 2002193568
                            20021219
                       A1
                            19971120
PRAI US 1997-66213P
                       Р
     WO 1998-US24949
                       W
                            19981120
                       Р
     US 1999-172464P
                            19991217
     US 2000-554537
                       A2
                            20000512
     US 2000-736836
                       A2
                            20001214
              THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE.CNT 7
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
=> d 13 ab
     ANSWER 13 OF 39 CAPLUS COPYRIGHT 2004 ACS on STN
L37
     The present invention provides altered lac repressor proteins
AB
     that recognize the lactose operator but have an
     altered ligand responsivity. The altered lac repressor
```

proteins contain a DNA-binding domain of the natural lac repressor protein and a ligand binding domain having a responsivity to an alternate inducer ligand or increased sensitivity to isopropyl-β-D-thiogalactoside (IPTG). The altered ligand responsivity provides that a sugar or other small mol. other than allolactose or IPTG acts as an inducer for the altered lac repressor protein or that IPTG acts at lower concns. The altered lac repressor proteins can further comprise a tetramerizing domain of the natural lac repressor protein. sequences encoding the altered lac repressor proteins and bacterial and eukaryotic cells containing altered lac repressor proteins are also provided. The invention also provides methods for preparing the altered lac repressor proteins including: (1) fusing the DNA-binding domain of natural lac repressor protein to the N-terminus of a ligand binding protein (such as arabinose binding protein) having responsivity to a ligand other than allolactose or IPTG or (2) fusing a tetramerizing domain of the natural lac repressor protein to the C-terminus of the ligand binding protein The invention also included the amino acid sequences of Escherichia coli lac repressor and arabinose-binding protein, which were used in constructing the fusion protein.

WEST Search History

Hide Items Restore Clear Cancel

DATE: Tuesday, July 27, 2004

Hide?	Set Name	Query	Hit Count
	DB=PGB	PB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YE	S; OP=OR
	L7	L6 not 14	29
	L6	L5 and operator\$	29
1/11	L5	(board)near2(regents)near3(texas)	258
	L4	12 and repressor\$	9
	L3	L2 and (fusion or fused)near10(peptide\$ or protein\$)	13
	L2	kodadek	45
	DB = USI	PT; PLUR=YES; OP=OR	
	L1	(6613582).pn.	1

END OF SEARCH HISTORY